Howard M. Gebel

Overview

Best Publications

• Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.

  Brian D. Tait;Caner Süsal;Howard M. Gebel;Peter W. Nickerson

  886
  Citations

• Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk.

  Howard M. Gebel;Robert A. Bray;Peter Nickerson

  491
  Citations

• Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis

  Nasir Rana;Donald P. Braun;Robert House;Howard Gebel

  369
  Citations

• Transplanting the highly sensitized patient : The emory algorithm

  R. A. Bray;J. D. L. Nolen;C. Larsen;T. Pearson

  293
  Citations

• Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report.

  Anat R. Tambur;Patricia Campbell;Frans H. Claas;Sandy Feng

  286
  Citations

• Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

  Carlos A. Vieira;Avinash Agarwal;Benita K. Book;Richard A. Sidner

  272
  Citations

• Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody

  Denise L. Faustman;Ralph M. Steinman;Howard M. Gebel;Vera Hauptfeld

  272
  Citations

• Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA.

  Elaine F. Reed;Ping Rao;Zilu Zhang;Howard Gebel

  254
  Citations

• Revisiting Traditional Risk Factors for Rejection and Graft Loss After Kidney Transplantation

  T. B. Dunn;H. Noreen;K. Gillingham;D. Maurer

  252
  Citations

• Sensitization and sensitivity: defining the unsensitized patient.

  Howard M. Gebel;Robert A. Bray

  252
  Citations

• Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report.

  Anat R. Tambur;Patricia Campbell;Anita S. Chong;Sandy Feng

  194
  Citations

• HLA Antibody Detection With Solid Phase Assays: Great Expectations or Expectations Too Great?

  H. M. Gebel;R. A. Bray

  189
  Citations

• APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.

  Barry I. Freedman;Stephen O. Pastan;Ajay K. Israni;David Schladt

  175
  Citations

• Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

  Barry I. Freedman;Bruce A. Julian;Stephen O. Pastan;Ajay K. Israni

  169
  Citations

• Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test.

  Thomas C. Fuller;Donna Phelan;Howard M. Gebel;Glenn E. Rodey

  165
  Citations

• The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities.

  Robert A. Bray;Lauralynn K. Lebeck;Howard M. Gebel

  158
  Citations

• Evolution of HLA antibody detection: technology emulating biology.

  Robert A. Bray;Peter W. Nickerson;Ronald H. Kerman;Howard M. Gebel

  157
  Citations

• De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.

  Robert A Bray;Howard Gebel;R. Townsend;M. E. Roberts

  147
  Citations

• Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants.

  Wasim A Dar;A. Agarwal;C. Watkins;H. M. Gebel

  144
  Citations

• Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors

  Allan D. Kirk;Antonio Guasch;He Xu;Jennifer Cheeseman

  142
  Citations

• Multidrug resistance activity in human lymphocytes.

  John S. Coon;Yazhang Wang;Steven D. Bines;Penelope N. Markham

  137
  Citations

• Translational Applications of Flow Cytometry in Clinical Practice

  David L. Jaye;Robert A. Bray;Howard M. Gebel;Wayne A. C. Harris

  136
  Citations